Contact Us

WELCOME TO

Covalence Pharma

A disrupter of generic drug development

Contact Us
Portrait of beautiful young woman preparing test samples while using microscope in laboratory, copy space

ABOUT US

High-quality generic pharmaceutical products to the global healthcare market

Covalence Pharma is a rapidly growing specialty pharmaceutical company focused on identifying, and developing generic prescription, over the counter and cosmetic products for importation, exportation, sales and distribution throughout the global market.

We are committed to bringing high-quality generic pharmaceutical products to the global healthcare market by leveraging our international industry partnerships, internal expertise and strategic operations. Our targeted growth strategy focuses on making our products available to physicians and patients in all markets across the globe.

Through licensing agreements, and development of our own active pharmaceutical ingredients and drugs coming off patent, we continue to add to our product portfolio.

Our products span across a variety of therapeutic areas and multiple dosage forms. We have a robust pipeline of pharmaceutical products through the development of that includes 505(b)(2), ANDAs, and foreign filings.

Our efforts to acquire, license, develop, market, sell and distribute high quality generic pharmaceutical products to global markets will allow us to establish a comprehensive portfolio supporting key therapeutic categories that meet customer needs. Through continued development and life-cycle management we will establish ourselves as a leader in the healthcare products industry.

Leadership

Our Team

Dr. Jamil Hantash, MD PhD, MBA

With more than 30 years hands on experience in non-clinical and clinical drug development Dr Hantash leads the scientific team at Covalence. 

 

Dr Jamil Hantash, MD PHD; MBA

With more than 30 years hands on experience in non-clinical
and clinical drug development Dr HANTASH leads the
scientific team at Covalence. He lead teams in global
pharmaceutical and research organizations before he
become the founder of the group of companies that started in 2014, few of the positions are Scientific fellow at Merck, Ex VP of Pharmaceutical services at Intertek, Sr Director at LabCorp, Direct at Covance and Study Director at Charles River Laboratories. Dr HANTASH also own Phase 2 to 4 Research Clinics in Chicago and Missouri in the USA (under
the name Healthcare Research Network LLC). Dr Hantash
started a clinical research organization to manage wound care studies in Florida in 2024 (under the name Capisecure
LLC). The Artificial intelligence and data modeling space had
Dr HANTASH interested and he started a PK/TK as well as PBPK non clinical and clinical data modeling and adverse effect prediction tool that is used to support pharmaceutical companies to minimize the risk of the expensive clinical trials
(under the company Fulcrum INC in Montreal in Canada).

See More

Owen Van Cauwenberghe, PhD

Dr. Van Cauwenberghe has over 20 years of strong pharmaceutical development leadership success, a broad research background and training in business administration.  

Owen Van Cauwenberghe, PhD

He started his career as a research scientist at Eli Lilly Canada where he had global positions of increasing responsibility to become Director of the Canadian Analytical Research Laboratories where he led the development of small and large molecule therapeutics. Following this, Dr. Van Cauwenberghe held multiple Director level roles at Accucaps Industries Ltd., where he helped transform the organization into a pharmaceutical development and commercial organization supporting several top tier brand pharma companies by growing and delivering a global products, capability, and technology development portfolio through leadership of formulation, analytical, innovation and project management organizations. Over the last 9 years Dr. Van Cauwenberghe has successfully owned and operated his own consulting companies (Bio Therapeutic Molecules Inc. and The VanC Group Inc.) helping global start-ups and established businesses identify opportunities within the life sciences sector, bring together sound science, technology, process, and business rigor, and build competitive businesses. By leveraging industry experience and networks and by applying a hands-on approach in the planning and execution of services he has been able to create value through holding multiple roles including executive, advisory and board member positions for several organizations in multiple verticals. Dr Cauwenberghe leads the North America operation.

See More

Verkin Khajadourian, MSc MBA

Mrs Khajadourian has extensive leadership experience in analytical and bioanalytical science supporting drug development in non-clinical and clinical space. 

Verkin Khajadourian, MSc MBA

Mrs Khajadourian has 25 plus years experience in new and generic drug development. She started her career as a Research Scientist within Charles River’s Laboratory Sciences team where she oversaw the development and validation of analytical methods for small and large molecules in formulation in support of nonclinical studies. She then joined the large molecule bioanalytical group at CRL where she gained hands on experience in developing TK and immunogenicity assays to detect drug quantities in plasma and immune response of therapeutic drugs over time in animals and humans after dosing.

After 10 years working in operations, Verkin transitioned to commercial where she took on various roles in Business Development/Scientific Liaison. With her experience and knowledge in analytical and bioanalytical sciences, she helped small and medium sized biotech companies get their drugs into human trials.

Verkin has held many leadership roles with increasing responsibilities in global CROs like Charles River and Intertek Pharmaceuticals. She is a great asset in the analytical and bioanalytical domain for the generic drug development.

See More

Dr Dale Christensen, PhD

Since the formation of Covalence Pharma (COV), Dr. Christensen has successfully translated three programs from concept to Phase 1 clinical trials and leads the non-clinical and clinical development activities for COV. 

Dr Dale Christensen, PhD

Since the formation of Covalence Pharma (COV), Dr. Christensen has successfully translated three programs from concept to Phase 1 clinical trials and leads the non-clinical and clinical development activities for COV. He is a biotech executive with over 25 years of Research and Development experience at the therapeutic interface of chemistry and biology experience managing research and early development across respiratory, inflammation, CNS, anti-infective, and oncology indications. Dr. Christensen also holds an appointment as Adjunct Associate Professor of Medicine at Duke University Medical Center. He has held senior positions at Spyryx Biosciences, Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA (formerly Novalon Pharmaceuticals).
In addition to running research programs for each company, he has also provided oversight of clinical trial design and execution; biomarker development; toxicology study design and execution; and CMC activities for multiple compounds, filing IND/CTA/CTNs, and early-stage trials. Dr. Christensen has been involved in companies that have raised more than $100M in funding from venture capital groups and $50M in public markets. In addition, he has negotiated strategic partnerships with large pharma and managed external alliances with both large pharma and academic labs.

See More

Dr Alaa Jadallah, Pharm D.

Dr Jadallah has extensive experience as a pharmacist in the marketing intelligence and portfolio management of selecting Generic drugs that are essential and difficult to develop. He has been instrumental in selecting the portfolio.

 

Dr Alaa Jadallah, Pharm D.

Dr Jadallah has extensive experience as a pharmacist in the marketing intelligence and portfolio management of
selecting Generic drugs that are essential and difficult to
develop. He has been instrumental in selecting the portfolio.
He has held marketing and portfolio management positions in GSK previously.

See More

Lisa Apolis, RAC

Lisa is a Certified Regulatory Affairs Professional with over 20 years of experience establishing and directing regulatory strategy for multiple domestic and global pharmaceutical companies.

 

 

Lisa Apolis, RAC

Lisa is a Certified Regulatory Affairs Professional with over 20 years of experience establishing and directing regulatory strategy for multiple domestic and global pharmaceutical companies leading to the submission and approval of generic drug products with US FDA. As a recognized regulatory expert in generic drugs, she has a solid ability to interpret and evaluate FDA and ICH regulations and guidelines for their impact on strategic regulatory and development plans for generic pharmaceuticals.  Lisa has successfully coordinated, managed and submitted over 75 ANDAs gaining US approval for multiple dosage forms including combination products.  She has an excellent working relationship with the Office of Generic Drugs (OGD), and oversees all communications with FDA. She has successfully led technical meetings with OGD which resulted in the acceptance of new regulatory strategies. Throughout her regulatory career, Lisa has provided leadership at all stages of the generic drug development, approval and lifecycle management process, including site transfers and oversight of the pharmacovigilance program.  With a background in Quality Control and Assurance, Lisa provides a unique ability to translate the regulations into actionable steps to ensure high-quality and compliant submissions. Lisa is a member of the Regulatory Affairs Professional Society (RAPS) and the Parenteral Drug Association (PDA), and an active participant in several OGD and FDA conferences.  Lisa holds a Bachelor of Science in Chemistry from the University of Tennessee and a graduate certificate in Pharmaceutical & Biomedical Regulatory Affairs from the University of Georgia.  In addition, she holds a certificate in Pharmaceutical Regulatory Affairs and has maintained her Regulatory Affairs Certified (RAC) credential since 2008. 

See More

Assad Aslam, BSc

With over 25 years of experience, Mr Aslam is the chief Financial and Investment officer that provides research and development advisory services, dilutive and non-dilutive capital financing strategies; intellectual property development; and project management navigator services to all our sites worldwide.

Assad Aslam, BSc

With over 25 years of experience, Mr Aslam is the chief Financial and Investment officer that provides research and development advisory services, dilutive and non dilutive capital financing strategies; intellectual property development; and project management navigator services to all our sites worldwide. Mr Aslam provides a combination of in-depth industry knowledge, regulatory navigation/strategies and high-quality commercial transaction expertise in the public and private sectors:

- Life Sciences
- AI platforms and Associated Technologies
- Consumer and E-Commerce Platforms

Mr Aslam is great at developing a well-thought-out plan is the first step towards achieving commercialization goals. While the general steps in development are the same for any product, the particulars of any given intellectual property creates nuances that must be addressed individually. Early creation of a strategic plan not only identifies those nuances pro-actively, but also allows the astute organization the opportunity to effectively forecast resource needs, both human and financial. A good strategic plan is like a roadmap for development, showing the starting point, the destination and the path to get from start to finish.

Mr Aslam’s customized strategic plan will also identify where we need to “fuel up” along the way to keep the organization properly funded. To suit our needs, he generates strategic plans with various levels of detail, from “35,000 foot” overviews for presentation to investors, to multi-tiered strategies with hundreds of detailed tasks ready to be executed by project managers. Mr Aslam plans can be tailored to a specific near-term goal or can incorporate all aspects of development, encompassing all types of intellectual properties and phases.

See More

We have Global Presence

Map3

Amman Jordan

Riyad Saudi Arabia

Toronto, Canada

Milan, Italy

Shanghai China

Hyderabad india

Johannesburg South Africa

Melbourne Australia

Dubai UAE

London, UK

NJ USA

Covelance Pharma

Menu
Menu
Copyright © 2025 All rights reserved